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ABSTRACT
FMR1 encodes an RNA-binding protein whose
absence results in fragile X mental retardation.
In most patients, the FMR1 gene is cytosine-
methylated and transcriptionally inactive. NRF-1
and Sp1 are known to bind and stimulate the active,
but not the methylated/silenced, FMR1 promoter.
Prior analysis has implicated a CRE site in regulation
of FMR1 in neural cells but the role of this site is
controversial. We now show that a phospho-CREB/
ATF family member is bound to this site in vivo.
We also find that the histone acetyltransferases
CBP and p300 are associated with active FMR1 but
are lost at the hypoacetylated fragile X allele.
Surprisingly, FMR1 is not cAMP-inducible and
resides in a newly recognized subclass of CREB-
regulated genes. We have also elucidated a role
for NRF-2 as a regulator of FMR1 in vivo through
a previously unrecognized and highly conserved
recognition site in FMR1. NRF-1 and NRF-2 act addit-
ively while NRF-2 synergizes with CREB/ATF at
FMR1’spromoter. These data add FMR1tothe collec-
tionofgenescontrolledbybothNRF-1andNRF-2and
disfavor its membership in the immediate early
response group of genes.
INTRODUCTION
Fragile X syndrome results from the loss of functional FMR1
gene product. This protein, FMRP, binds brain mRNA and
therefore is important in nucleic acid metabolism [for a
review see (1)]. In almost all fragile X patients, disease is
due to transcriptional silencing of FMR1 which occurs after
expansion of a trinucleotide repeat in the 50-untranslated
region (50-UTR) of FMR1. Expansion triggers aberrant and
permanent DNA methylation and heterochromatin formation
and yields an FMR1 promoter that lacks its activators (2–6).
Demethylation of FMR1 can be achieved in fragile X cell lines
by treatment with 5-azadeoxycytidine which restores tran-
scription factor function and an active state of chromatin
(7–11).
In designing strategies to reactivate FMR1 transcription, not
only it is important to understand the functions of the silencing
factors, but also it is crucial to know the identities and con-
tributions of the transcription factors and co-activators norm-
ally controlling FMR1. Silenced FMR1 in fragile X syndrome
is marked by a loss of histone acetylation, compared with
the active FMR1 gene (8). However, it is not known which
proteinsare responsible fornormallymaintaininghistone acet-
ylation at active FMR1. In addition, signiﬁcant questions
regarding the exact identities and functions of the transcription
factors controlling FMR1 are still unanswered.
Four in vivo footprints were initially identiﬁed in the FMR1
promoter in primary and transformed cells of ﬁbroblast and
lymphoblast origin (12,13). Several proteins can bind the
FMR1 promoter in vitro, including CREB, AP-2, Sp1, nuclear
respiratory factor 1 (NRF-1) and upstream stimulatory factors
1 and 2 (henceforth referred to collectively as USF) (14–17).
However, these initial studies have left unanswered questions
regarding FMR1 transcription in vivo. We have previously
shown that Sp1, NRF-1, USF and Max are bound speciﬁcally
to the active FMR1 promoter in vivo and that Sp1 and NRF-1
were strong synergistic activators of FMR1 transcription (18).
Recent work by others has shown that AP-2a may serve as a
positive regulator of FMR1 transcription during development
(19). Not all transcription factors bound at FMR1 in vivo are
positively acting. In addition to Max-mediated repression of
FMR1 transcription, we found that USF was unable to activate
an FMR1-driven reporter in Drosophila SL2 cells, and indeed,
strongly repressed Sp1 and NRF-1 mediated activation of
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doi:10.1093/nar/gkj521FMR1 (18). In addition, repression was not dependent on the
E-box (18). This result was surprising, since mutation of the
E-box has been shown to lower FMR1 transcription by  75%
in PC12 cells and it has been speculated that USF operates
through this site in vivo (16).
Therefore, it is still unclear which proteins are actually
acting through the initially identiﬁed footprint over the
E-box, which lies nearest to the transcription start site. It
has been especially confusing since early experiments showed
that a potential cAMP-responsive element (CRE) overlaps this
E-box, suggesting that CREB may transduce neuronal stimuli
and thereby impact FMR1 transcription in brain (14). Despite
early evidence, most subsequent reports have either not
addressed this issue or obtained data that does not support
this ﬁnding. For example, two in vivo footprinting reports
showed data suggestive of proteins binding the E-box; how-
ever, both reports indicated that the partly overlapping CRE
site was not occupied albeit neither study examined neuronal
cell types (12,13). In addition, EMSA analyses with an FMR1
promoter fragment and nuclear extract failed to show that
CREB could bind this site (16). Instead, USF bound
in vitro to an FMR1 promoter fragment and it was suggested
that the E-box could be occupied by this factor in vivo
(12,13,16). Furthermore,thereisno evidence that CREB occu-
pies the FMR1 promoter in normal cells nor has a functional
histone acetyltransferase been identiﬁed for this highly acet-
ylated portion of chromatin.
Since our experiments with USF in vivo contradicted the
proposed function that USF transactivates FMR1, we have
now examined both CREB and USF at FMR1 in human
cells. USF represses FMR1 reporter activity in HeLa cells
suggesting that USF does not naturally regulate FMR1 tran-
scription through the E-box. Instead, we show occupancy of
the active, but not inactive promoter, by the CREB/ATF fam-
ily of transcription factors in vivo as well as the histone acet-
yltransferases CBP and p300. Surprisingly, we ﬁnd that the
endogenous FMR1 gene in PC12 neuronal-like cells is not
cAMP-inducible. We also learned that nuclear respiratory fac-
tor 2 (NRF-2) is bound to FMR1 in normal but not patient cells
and can transactivate the promoter. This is the ﬁrst implication
of this site or transcription factor at FMR1 and is congruent
with earlier evidence that NRF-1 is known to operate with
NRF-2 to coordinately control the transcription of genes
involved in mitochondrial respiration and biogenesis (20).
These data strongly suggest that CREB/ATF family members
and not USF regulate FMR1 transcription through the E-box/
CRE, and together with NRF-2, positively contribute to FMR1
expression. These ﬁndings lend new insight into the regulatory
network to which the important RNA-binding protein, FMRP,
belongs.
MATERIALS AND METHODS
Plasmid construction
Construction of pFMR1-luc, which contains a human
FMR1 promoter fragment ( 272 to +291) driving ﬁreﬂy
luciferase expression and mutation of the E-box/CRE
in the FMR1 promoter have been described previously
(18). Mutation of the NRF-2 site in pFMR1-luc was per-
formed by site-directed mutagenesis with the following
oligos: 50-CGTTTCGGTTTCGTTAACGGTGGAGGGC-30
and 50-GCCCTCCACCGTTAACGAAACCGAAACG-30
which introduce a HpaI site into the NRF-2 binding site;
the mutation was conﬁrmed by sequencing. pACTIN-
FL-NRF-1 contains full-length human NRF-1 with an N-
terminal FLAG tag and pRL-dA5C contains the Renilla
luciferase gene; both constructs are driven by the Drosophila
actin 5C promoter and were constructed as described previ-
ously(18).Avector expressingfull-lengthratCREB wasagift
from Dr Jerry Boss. Vectors expressing full-length human
USF1 (pSV-USF1) or mouse USF2 (pSV-USF2) were gifts
from Dr Michele Sawadogo (21). Dominant negative USF
(A-USF) expression vector and empty control were gifts
from Dr Charles Vinson (22,23). Vectors encoding full-
length human NRF-2-alpha (A5CDP-GABPa), NRF-2-beta
(A5CDP-GABPb) and ATF-1 (A5CDP-ATF1) for expression
in Drosophila cells, were gifts from Dr Hiroshi Handa (24,25).
A luciferase reporter construct containing the human
HO-1 promoter (pHOGL3/4.5) was a gift from Dr Anupam
Agarwal (26).
Cell culture and transfections
HeLa, SL2 and lymphoblastoid cell culture was carried out as
described previously (18). Lymphoblastoid cell lines from a
normal male (J-1) and a fragile X male patient (GM3200A)
were obtained from Coriell Cell Repositories. J-1 contains an
unmethylated 30 CGG repeat allele and GM3200A carries a
methylated 530 CGG repeat allele as determined by methyl-
sensitive restriction digest and Southern blot analysis (data not
shown). PC12 cells were grown in DMEM (Cellgro) with 10%
horse serum (Gibco), 5% FetalClone I (Hyclone), 100 U/ml
penicillin and 100 mg/ml streptomycin, in a humidiﬁed
atmosphere at 37 C. HeLa cell transfections were carried
out using Lipofectamine Plus (Invitrogen) as described previ-
ously (18). Each sample contained 200 ng of either mutant
or wild-type pFMR1-luc reporter and 50 ng of the Renilla
luciferase reporter pRL-cytomegalovirus (CMV) (Promega).
In addition, transfections with wild-type USF contained
250 ng of either pSV-USF1 or pSV-USF2 expression plas-
mids, or 125 ng of pSV-USF1 and 125 ng of pSV-USF2, or an
equal amount of empty expression vector. Alternatively, 100
or 200 ng of A-USF or empty expression vector were included
in transfections as indicated. SL2 transfections were per-
formed using Effectene (QIAGEN) as described previously
(18). Samples contained 250 ng of either mutant or wild-
type pFMR1-luc reporter and 25 ng of pRL-dA5C. Transfec-
tions also included one or more of the following, as indicated
in each ﬁgure: 300 ng of pACTIN-FL-NRF-1, 700 ng of NRF-
2 which corresponds to 350 ng of each A5CDP-hGABPa
and A5CDP-hGABPb expression plasmids, 300 ng of ATF-
1 expression plasmid (A5CDP-hATF1) or empty vector.
Where necessary, empty expression vector was added to
keep total DNA levels constant between samples.
Antibodies, chromatin immunoprecipitation (ChIP)
and forskolin treatment
Antibodies to CBP (A-22), p300 (C-20) and GABP-alpha
(H-180) were purchased from Santa Cruz Biotechnology.
Phospho-CREB antiserum was a gift from Dr Jerry Boss.
ChIP in lymphoblastoid cells was performed as described
1206 Nucleic Acids Research, 2006, Vol. 34, No. 4previously (18). ChIP in PC12 cells was done essentially the
same way, with a few exceptions. PC12 cells at  60–80%
conﬂuencywere growninDMEMcontaining0.5%FetalClone
I (HyClone) and treated the next day with 10 mM forskolin
(Sigma) or an equal volume of dimethyl sulfoxide (DMSO) for
25 min. Formaldehyde was added to the media for 20 min and
whole cell extracts were prepared for ChIP. For the rat c-fos
promoter, primers were 50-CCTACATGCGGAGGGTCCAG-
GAGAC-30 and 50-GAGTAGTAGGCGCCTCAGCTGGCC-
30. For the rat FMR1 promoter, primers were 50-CTCTT
GGGCAGCTGAGCACGC-30 and 50-GGCCATAGGCAG-
CACGACCTG-30. For GABP-alpha ChIPs, primers used to
amplify the human Tfam promoter were 50-CGAGCTC-
CAGCCCTGGCTTGAAC-30 and 50-CCTCGCGGGGGAG-
GAATAAGAGC-30 and primers for the human FMR1
promoter were 50-CTACGGGTCACAAAAGCCTGGGT-
CACC-30 and 50-GCAGTCTGACTGAGCGGGAGGTG-
GAG-30. For CBP, p300 and P-CREB ChIPs, primers for
the human c-fos promoter were 50-GCTTGTTATAAAAG-
CAGTGGCTGCG-30 and 50-GTTGAAGCCCGAGAACAT-
CATCG-30 and primers for the human FMR1 promoter
were 50-CGACTCAATCCATGTCCCTTAAAGG-30 and
50-CCAGTTCGGCCTCTCTGGGATTCC-30. Cycling condi-
tionswere94 Cfor2min, 33cyclesof94 Cfor45s, 64 C(rat
and human c-fos and FMR1 promoters) or 68 C (human Tfam
and FMR1 promoters) for 50 s and 72 C for 45 s, followed by
72 C for 7 min. PCR products were separated by gel electro-
phoresis through 1.5% agarose and bands were detected by
ethidium bromide staining.
Quantitative RT–PCR
Quantitative PCR was performed on a BioRad iCycler using
SYBR green. Cycling parameters were 95 C for 3 min, 46
cycles of 95 C for 15 s and 64 C( c-fos, FMR1 and Tfam
promoters) or 60 C( FMR1, c-fos and HPRT transcripts)
for 50 s, then 1 cycle of 95 C for 50 s and 55 C for 50 s.
Primers to amplify the rat FMR1 transcript were 50-GCATTT-
GTAAAAGATGTCCATG-30 and 50-CAAGGCTCTTTTT-
CATTTGCTC-30, for the rat c-fos transcript, primers were
50-GGAGCTGACAGATACGCTCCA-30 and 50-GATCTTG-
CAGGCAGGTCGGT-30 and for the rat HPRT transcript
primers were 50-CGTGATTAGTGATGATGAACCAGG-30
and 50-ATGTAATCCAGCAGGTCAGCAAAG-30. Tran-
script levels for FMR1 and c-fos were calculated from a
standard curve and normalized to HPRT mRNA levels.
Primers for real-time PCR of the rat c-fos promoter
were 50-CCTACATGCGGAGGGTCCAGGAGAC-30 and
50-CCCTGTCATCAACTCTACGCCCCA-30. Primers for
real-time PCR of the rat FMR1 promoter were 50-CCAGCG-
CAGTGAAAAATGTACC-30 and 50-GTACAGGAGGAA-
GCGAGGACG-30. For the human FMR1 promoter, primers
were 50-GGAATGTAAAGGGTTGCAAGGAGG-30 and
50-CACTTGAGGTTCATTTCTGCCCC-30. Human c-fos
promoter primers were 50-GCTTGTTATAAAAGCAGT-
GGCTGCG-30 and 50-GTTGAAGCCCGAGAACATCA-
TCG-30 and human Tfam promoter primers were
50-GGTCCTGGATGCAGGACTGTCTG-30 and 50-GGAAA-
CCGCAATCCTCTAGCCTGC-30. Relative amounts of
promoter DNA isolated after ChIP were calculated from a
standard curve of input DNA for each promoter.
RESULTS
USF represses FMR1 promoter activity in
mammalian cells
We have previously shown that USF represses FMR1 reporter
activity in Drosophila SL2 cells (18). This result was unex-
pected, as mutation of the site through which it has been
proposed to operate, the E-box/CRE (Figure 1), lowers expres-
sion to about 20% of normal in HeLa cells indicating it oper-
ates in a positive manner (Figure 2A). This is similar to prior
observations in rat PC12 cells (16), and led us to explore the
role of USF at FMR1 in human cells. We found that overex-
pression of USF1, USF2 or a combination of both, repressed
FMR1 reporter activity in HeLa cells between 45 and 60% and
repression was largely independent of the E-box (Figure 2B).
To rule out the trivial possibility that this repression was due
to overexpression of USF, we employed a dominant negative
USF (A-USF) that binds the endogenous USF proteins and
prevents them from interacting with DNA (22). Overexpres-
sion of A-USF in HeLa cells did not change FMR1-luc expres-
sion although the HO-1 promoter, previously shown to be
controlled by USF, was repressed in a dose dependent manner
(Figure 2C) (26). These results suggest that USF does not
normally contribute in a positive way to FMR1 core promoter
activity in HeLa cells.
FMR1 is bound in vivo by a phosphorylated CREB/ATF
family member, as well as CBP/p300, but is not
cAMP-inducible
Since our results suggested that USF is not responsible for the
previously described footprint over the E-box, we turned our
attention to a potential CRE in the human FMR1 promoter
Figure 1. HumanFMR1promotermapshowingthe fourbindingsitesknowntobe occupiedin vivoandthe identitiesofthe likelyfactorsat thosesites(12,13). The
sequenceoftheoverlappingE-box/CREisshownunderneaththesiteandthatoftheE-box/CREmutantusedinreporterassaysisshownbelowthewild-typesequence
withmutatedbasesunderlined.AquestionmarkabovetheE-box/CRErepresentstheunknownfactor(s)bindingthissiteinvivo.Thebentarrowindicatesthemajor
transcription start site (61).
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across species (12–14,16). It was initially shown that recom-
binant CREB can bind an FMR1 promoter fragment in vitro
and that overexpression of CREB could increase activity from
an FMR1-driven reporter (14). However, subsequent reports
suggested that the CRE is not involved in FMR1 transcription,
though none directly test CREB’s role in vivo (12,13,16).
Since our results suggested that USF is not acting through
the E-box, we tested the idea that CRE-binding proteins reside
at this site.
Since initial experiments suggested that a CRE-binding
protein could act at FMR1 and that this gene may be induced
by the cAMP pathway, we employed ChIP using an antibody
raised against CREB phosphorylated at Ser 133 (J. Lochamy
and J. Boss, manuscript submitted). Indeed, we found that a
phosphorylated CREB/ATF family member was bound at the
active human FMR1 and c-fos promoters in lymphoblastoid
cells, but not at silenced FMR1 in fragile X cells (Figure 3A).
This was speciﬁc for FMR1, since P-CREB occupied the c-fos
promoter in fragile X cells (Figure 3A). Since a P-CREB
family member was bound at FMR1, we also tested if the
histone acetyltransferases CBP and p300 that bind P-CREB
were associated with active FMR1, which shows robust
histone acetylation (8). Indeed, both histone acetyltransferases
reside at FMR1 and their presence was largely reduced at the
fragile X allele (Figure 3B).
We then used undifferentiated PC12 cells to test if the
endogenous FMR1 gene is cAMP-inducible. Cells were trea-
ted with 10 mM forskolin or DMSO (vehicle). Real-time PCR
of endogenous c-fos showed its strong induction ( 50-fold) at
1 h post-stimulation (Figure 4A). However, FMR1 and HPRT
transcript levels did not change (Figure 4A and data not
shown). Even after 24 h, FMR1 mRNA levels remained con-
stant (data not shown) revealing that in contrast to previous
suggestions, the endogenous FMR1 gene is not cAMP-
inducible in this cell type. We also obtained similar results
after KCl/CaCl2 treatment of PC12 cells (data not shown).
Since it has been shown that at c-fos, the phosphorylation
of CREB increases in response to forskolin treatment, and
this is followed by induction of transcription, we tested if
phosphorylation of CREB/ATF at FMR1 changed after for-
skolin treatment. We found that the CRE-binding proteins at
FMR1andc-foswere phosphorylatedinundifferentiated PC12
cells without forskolin treatment (Figure 4B, upper panel). We
performed quantitative analyses of P-CREB binding at c-fos
and FMR1 and found that in response to forskolin treatment,
the increase in occupancy of the phosphorylated CRE-binding
protein on FMR1 was  2.2-fold (Figure 4B, lower left
panel), while that on c-fos was  4.6-fold (Figure 4B, lower
right panel).
Identification of a conserved consensus NRF-2
binding site in the FMR1 50-UTR
Previous FMR1 promoter analysis identiﬁed several protein
binding sites conserved among species (16). Using homology
alignment, we found another evolutionarily conserved tran-
scription factor binding site that had not been previously iden-
tiﬁed (Figure 5A). The conservation of the GTTT sequences 50
to the boxed NRF-2 site suggests these bases are also import-
ant NRF-2 contacts (Figure 5A). Since recent work has shown
Figure 2. USF does not regulate transcription through the E-box. (A) HeLa
cells were transfected with wild-type pFMR1-luc or with pFMR1-luc with
point mutations in the E-box/CRE and luciferase activities were measured
in cell lysates. (B) Either the wild-type (left) or E-box/CRE mutant reporter
(right) was transfected into HeLa cells with or without pSV-USF1 and/or
pSV-USF2 expression vectors as indicated. (C) pFMR1-luc or pHOGL3/4.5
wastransfectedintoHeLacellswiththeindicatedamountofA-USFexpression
plasmid, or empty vector. Values for the FMR1 or HO-1 promoters were
normalized to a CMV transfection control reporter. Data are expressed as
percent normalized luciferase activity. Error bars represent ±1 standard
deviation.
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ﬁsh, as well as Xenopus, are conserved compared to humans,
we looked to see if the promoter sequences for FMR1 may also
be conserved in these animals (27,28). We have now extended
thealignmentoftheFMR150 regiontoinclude sequences from
Danio rerio, Xenopus tropicalis as well as Gallus gallus
(Figure 5A). A TATA-like motif and the NRF-2 site are
conserved among all species tested, despite variations in the
intervening sequence (Figure 5A). In addition, recently avail-
able genomic sequence of the zebraﬁsh FMR1 gene shows
that, in addition to the TATA-like and NRF-2 elements,
sites representing the four in vivo footprints in the human
FMR1 promoter are also conserved (Figure 5B).
The NRF-2 site is positively acting and NRF-2
stimulates the FMR1 promoter
We tested the function of the putative NRF-2 site in the human
FMR1 promoter. Mutating four bases in the binding site
(Figure 5A) reduced FMR1 promoter activity to 40% of
wild-type in HeLa cells showing the importance of this site
for FMR1 expression (Figure 6A). To test if FMR1 was a bona
ﬁde NRF-2 target, we asked if NRF-2 was bound to active
FMR1 in human cells. Using ChIP and an antibody against its
DNA-binding (alpha) subunit, we found that NRF-2 is bound
to FMR1 in vivo (Figure 6B). As expected for an activator of
transcription, NRF-2 was not bound at the silenced, expanded
FMR1 allele in patient cells, although it occupies the active
Tfam promoter in these cells (Figure 6B).
We have previously shown the importance of NRF-1 in
FMR1 transcription (18). NRF-1 often works at promoters
with NRF-2; this is especially well documented for numerous
nuclear-encoded mitochondrial genes (20,29). To test
NRF-2’s transcriptional activity at FMR1, we asked whether
NRF-2 could activate the FMR1 promoter in SL2 cells which
have previously proven successful in assessing the function of
this transcription factor (25,30–32). As expected, transfection
of either NRF-2-alpha or NRF-2-beta alone had no effect
on FMR1 transcription (data not shown). However, co-
transfection of both subunits activated the FMR1 promoter
between 1.7- and 3.1-fold (Figure 7A and B). We then tested
if NRF-1 and NRF-2 could work together at FMR1 and found
that they activated transcription additively (Figure 7A). Since
members of the CREB/ATF family have been shown to work
with NRF-2 to synergistically activate transcription, we
wanted to test if this occurred at FMR1 (25). Indeed, we
found that ATF-1 activates FMR1 transcription synergisti-
cally with NRF-2 (Figure 7B). This result is similar to that
obtained with CREB and NRF-2 (data not shown). Import-
antly, mutation of either the E-box/CRE or the NRF-2
binding site abolished activation by ATF-1 and NRF-2
(Figure 7B).
DISCUSSION
The precise roles and relative importance of the many tran-
scription factors implicated in FMR1 promoter function is
controversial. Early reports suggested that FMR1 is regulated
by cAMP signaling, perhaps through CREB (14). Here we
show that CRE-binding proteins play a role in FMR1 tran-
scription, however the endogenous gene is not induced in a
manner such as that observed for the immediate early c-fos
gene. These data are consistent with our ﬁndings that USF
does not appear to operate through this region of the promoter
resolving the paradox that a protein resides at this site but that
USF does not activate this promoter. It is also worth noting
that Drosophila SL2 cells accurately predicted how USF
Input
B A
Figure3.P-CREB/ATFandCBP/p300occupyhumanFMR1invivo.(A)ChIPwascarriedoutwitheitheranti-P-CREBantibodyor(B)antibodiestoCBPandp300,
ornon-specific rabbitIgG[N.S. inboth(A andB)].PCRwasperformedto amplifythe FMR1andc-fospromotersinnormalandfragileXcells (left).Occupancyof
p300 was quantified by real-time PCR of an independent set of triplicate IPs (right); error bars represent ±1 standard deviation.
Nucleic Acids Research, 2006, Vol. 34, No. 4 1209proteins would act at the FMR1 promoter in a human cell line,
showing that this is a useful cell line for studying these human
transcription factors (18). Due to the overlapping nature of the
E-box and the CRE, it is unlikely that both could be occupied
at the same time by different transcription factors. However,
we cannot rule out the possibility that this overlapping site
could be differentially used by E-box binding factors and
CRE-binding proteins in different cell types. To date, there
is no direct in vivo evidence that USF is positively acting
through the E-box/CRE site at FMR1 in any cell type and
c-Myc is not present at FMR1 in vivo though other E-box
binding proteins could play a role (18). In vitro, USF can
bind to an FMR1 promoter fragment and induce bending of
an FMR1 promoter fragment (16,17). Curiously, our previous
Figure 4. FMR1 transcription is not cAMP-inducible. (A) Real-time PCR quantification of endogenous FMR1, HPRT and c-fos transcripts in PC12 cells with or
without1hofforskolinstimulation.(B)PhosphorylationofCREB/ATFatFMR1increases2-foldafterforskolininductionofPC12cells.ChIPwasperformedwithP-
CREB antiserum on DMSO- or forskolin-treated PC12 cells. PCR was performed to amplify the rat FMR1 and c-fos promoters (top). Quantification of P-CREB
binding was performed by real-time PCR (bottom). Error bars represent ±1 standard deviation. For FMR1 real-time analysis, two independent IPs are represented,
each with duplicate real-time PCR. For c-fos, the real-time data represent one IP with quadruplicate real-time PCR.
1210 Nucleic Acids Research, 2006, Vol. 34, No. 4in vivo ChIP results indicate that USF resides on the FMR1
promoter in lymphoblastoid cells however it does not regulate
the FMR1 promoter through the E-box (18).USF has alsobeen
shown to work through initiator (Inr) elements that surround
the transcription start site (33). However, mutation of an Inr
element in FMR1 did not affect promoter activity in reporter
assays (16). The recognition site for USF and its function at
FMR1 remain to be elucidated. Our data suggest that USF is
not acting in the  300 bp upstream of the transcription start
site and no incriminating in vivo footprints were identiﬁed up
to  600 bp upstream of the start site, although there is a
perfect consensus E-box at   800 bp from the transcription
start (12,13). If bound by USF, perhaps this site plays a role
in maintaining chromatin structure of FMR1 on the endogen-
ous locus and hence, its role, as determined using a minimal
promoter fragment on reporter plasmids and through in vitro
assays, has not been appreciated. Consistent with this idea,
USF has recently been implicated in recruiting histone
acetyltransferase activity at genomic regions suggesting that
these proteins could play a similar role at FMR1 (34).
In addition to clarifying which protein is working through
the E-box/CRE, we have found a new transcription factor
binding site on FMR1 that binds NRF-2/GA-binding protein
(GABP) in vivo. This site has remained unidentiﬁed as pre-
vious footprintinganalyseseither didnotcoverthisregion(13)
or did not ﬁnd evidence of a footprint in this area (12). Perhaps
the binding of NRF-2 to this site is not stable enough to be
detected reliably without the use of crosslinking agents. It has
been previously shown that NRF-2 binding is affected by
methylation of its recognition site (35–37). Indeed, our results
show thatNRF-2 doesnotoccupy the promoter inpatientcells,
thereby reinforcing the view that a global repression mechan-
ism shuts this gene off in patients. A role for NRF-2 at FMR1
follows from ourpreviousevidence showingthe importance of
NRF-1 in FMR1 expression. In addition to its role at FMR1,
potential NRF-1 sites have been reported in the promoters of
multiple other genes involved in translation and mRNA meta-
bolism, e.g. eIF2-alpha, eIF2-beta and hnRNP-A2 (12,38),
and we have discovered putative NRF-2 binding sites in all
of these promoters as well (data not shown). Thus, FMRP
could ﬁt into a ‘RNA metabolism’ regulon of genes controlled
by both NRF-1 and NRF-2, since it is an RNA-binding protein
associated with translation (1).
The best studied functions for NRF-1 and NRF-2, however,
are in controlling transcription of nuclear-encoded mitochon-
drial-related genes, notably the major transcription factor
Tfam, as well as mitochondrial transcription speciﬁcity factors
(20,39). It is not clear what separates or potentially links NRF-
1 and NRF-2 mediated regulation of mitochondrial-related
genes and those involved in RNA metabolism, or other
functions.
An important question is the inducibility of FMR1 promoter
function. Despite the suggestion made several years ago that
FMR1 may be cAMP-inducible, we are not aware of any
Figure 5. IdentificationandconservationofaNRF-2/GABPbindingsiteinthe50-UTRofFMR1.(A) SequencealignmentofFMR1homologsfromseveralspecies
showing a newly identified binding site for NRF-2. GenBank accession nos are as follows: L29074.1 (Homo sapiens), AY630337 (Rattus norvegicus), AY630338
(Mus musculus), AF251348 (Canis familiaris), AF251350 (Macaca arctoides), AF251349 (Pan troglodytes), NM_152963 (D.rerio), BC074570 (X.tropicalis) and
CR386208 (G.gallus). The major transcription start site as identified in humans is shown and numbering is based on the human FMR1 sequence (61). Nucleotides
conservedin allninespeciesareindicatedwithanasterisk.TheunderlinedbasesintheNRF-2humansequencerepresentthosechangedformutationalanalysisand
thechangesareshowninitalicsabovethesite.(B)IdentificationofthezebrafishFMR1promoter(GenBankaccessionno.BX005284)andalignmentwiththehuman
promoter (accession no. L29074.1). Boxes represent protein binding sites known to operate in humans that are conserved in zebrafish. Underlined sites represent
potential positional differences between the two species for these factors. Conserved nucleotides are denoted with an asterisk.
Nucleic Acids Research, 2006, Vol. 34, No. 4 1211reports that have tested this hypothesis on the endogenous
FMR1 gene. Phosphorylation of CREB was originally thought
to be speciﬁc and sufﬁcient for the cAMP-induction of genes.
Recent work, however, shows that genes can be bound by
Figure 6. NRF-2 is a regulator of FMR1 transcription in vivo.( A) HeLa cells
were transfected with wild-type or NRF-2 site mutant pFMR1-luc reporter
plasmids. Values for the FMR1 promoter were normalized to a CMV transfec-
tion control reporter. Data plotted are the average of six independent
transfections ±1 standard deviation. The wild-type reporter was arbitrarily
set to 100%. (B) Immunoprecipitation using an anti-NRF-2 antibody or non-
specific IgG (N.S.) was performed on chromatin from normal and fragile X
cells.Real-timePCRwascarriedoutontriplicateIPstoquantifythebindingof
NRF-2 to the Tfam and FMR1 promoters; error bars represent ±1 standard
deviation.
Figure 7. Stimulation of the human FMR1 promoter in Drosophila SL2 cells.
(A) pFMR1-luc reporter plasmid was co-transfected into SL2 cells with an
empty vector or vectors expressing NRF-1 (pACTIN-FL-NRF-1), or NRF-2
(both A5CDP-hGABPa and A5CDP-hGABPb) or both NRF-1 and NRF-2.
Firefly luciferase values are normalized to a Renilla luciferase control. The
fold-changes are shown above each bar in relation to the sample representing
pFMR1-lucalonewhich wassetto 1·. Eachbarrepresentsthe averageofthree
transfections and error bars represent ±1 standard deviation, except for NRF-2
for which the average of two transfections was plotted. (B) pFMR1-luc, or
pFMR1-luc with the NRF-2 or E-box/CRE sites mutated, were co-transfected
with vectors expressing human ATF-1 (A5CDP-hATF1), or NRF-2 (both
A5CDP-hGABPa and A5CDP-hGABPb) or both ATF-1 and NRF-2. The
fold-changes are shown above each bar, in relation to their appropriate
controls and are plotted in relative light units (RLU) on the vertical axis. Bars
represent the averages of at least three transfections. Error bars for all samples
represent ±1 standard deviation.
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have shown that even though FMR1 is bound by P-CREB/
ATF as well as by CBP/p300, it is not cAMP-inducible. An
important step in CREB/ATF function is the recruitment of
CBP/p300 to P-CREB (41). Sp1, NRF-1 and NRF-2, may also
play a role in recruiting CBP/p300 suggesting that these HATs
may be recruited to FMR1 through their interactions with
multiple transcription factors (42–47).
Interestingly, the overlapping E-box and CRE elements in
the FMR1 promoter are almost identical to the E-box/CRE site
in the human c-fos promoter with a one base pair difference
in the E-box: CCCGTGACGT versus FMR1’s: CACGT-
GACGT. However, we have shown that there are many
differences between the two genes and their regulation by
CRE-binding proteins. The co-existence of a TATA box
and a CRE within a promoter has been shown to correlate
with cAMP-responsiveness (48). The absence of a canonical
TATA box from the FMR1 promoter may partly explain its
non-responsiveness to cAMP. In this regard, FMR1 has many
characteristics of a housekeeping gene, including the lack of
a TATA box, a high GC content and its regulation by
factors such as NRF-1, NRF-2 and Sp1 (49,50). The prior
observation that an FMR1-driven reporter construct was
cAMP-inducible, may have resulted from the inclusion of
only a small fragment of the FMR1 promoter, which contained
the CRE but lacked the other FMR1 transcription factor bind-
ing sites (14).
FMRP has been implicated in synaptic plasticity suggesting
that, at some level, FMR1 expression may be responsive to
neuronal signals (51–53). However, FMR1 transcription was
not responsive to cAMP, or to depolarization which is known
to activate NRF-2 (54,55). Perhaps FMR1 does not need to be
induced at the transcriptional level in adult neurons since post-
translational changes modulate FMRP in response to certain
stimuli (56–58). For example, FMR1 mRNA and FMRP
rapidly localize in dendrites in response to treatment with
KCl and FMRP is quickly translated within 5 min of
mGluR stimulation of neurons (56,57). Even though these
stimuli activate CREB, it would take longer to make FMRP
through a transcriptional induction pathway than to directly
increase FMRP levels by post-transcriptional processes
(59,60). Hence, mobilization of pre-existing FMR1 mRNA
and protein, along with rapid local translation may be more
important for the neuronal functions of FMRP than new
mRNA synthesis. In support of this model, FMRP levels
increase in cortical neurons following stimulation by light
exposure, but mRNA levels do not change (58). A complete
description of the regulatory landscape of the FMR1 promoter
will facilitate the examination of the intrinsic developmental
and external neuronal signaling mechanisms by which regu-
lation of FMR1 is achieved.
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